scholarly journals Medical management and antiepileptic drugs in hypothalamic hamartoma

Epilepsia ◽  
2017 ◽  
Vol 58 ◽  
pp. 16-21 ◽  
Author(s):  
J. Helen Cross ◽  
Helen Spoudeas
Keyword(s):  
Antiepileptic Drugs ◽  
Medical Management ◽  
Hypothalamic Hamartoma

scholarly journals A meta-analysis of case-reports and case-series of dacrystic epilepsy in children and adolescence

2021 ◽  
Vol 8 (11) ◽  
pp. 1873
Author(s):  
Chandan Raybarman
Keyword(s):  
Antiepileptic Drugs ◽  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Relevant Information ◽  
Hypothalamic Hamartoma ◽  
Seizure Freedom ◽  
Mesial Temporal Sclerosis ◽  
Structural Abnormality ◽  
Gelastic Seizures

This meta-analysis aimed to advance our knowledge about dacrystic epilepsy in children in the present time. PubMed searches for peer-reviewed case reports and case series were conducted using the keywords “dacrystic epilepsy”, “dacrystic seizures”, “crying epilepsy”, “ictal crying”, “crying seizures”. The databases were developed in accordance with preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The author collected relevant information to characterise the study population including clinical outcome. Eleven studies out of 353 citations between 1998 and 26 May 2021 met the inclusion criteria, including both single cases and series pertaining to dacrystic epilepsy. Eight case reports and three case series were eligible for this meta-analysis and included twenty one cases. The seizure patterns were dacrystic seizures alone in seven cases (33%), and a combination of dacrystic seizures and gelastic seizures in fourteen cases (67%). Neuroimaging revealed structural abnormality in 95% cases. Hypothalamic hamartoma was found in most of the cases (79%) with combined dacrystic seizures and gelastic seizures, whereas it was found in one case (16%) with dacrystic seizures alone. The other underlying lesions in children with dacrystic seizures alone were subependymal nodules and cortical hamartomas (17%), left mesial temporal sclerosis (33%), and cortical dysplasia (17%). Regarding outcome, antiepileptic drugs alone achieved seizure freedom in four cases (22%) only and others (78%) were difficult to treat cases excluding three cases where treatments were not mentioned. Six cases underwent surgical intervention and two cases received ablative radiotherapy. Lesional dacrystic epilepsy is predominant and pharmaco-resistant in children. However, antiepileptic drugs lead to achieving seizure remission in few cases.

Epileptic Spasms in a Large Hypothalamic Hamartoma Cohort

2020 ◽  
pp. 088307382096865
Author(s):  
Cemal Karakas ◽  
Angus A. Wilfong ◽  
James J. Riviello ◽  
Daniel J. Curry ◽  
Irfan Ali
Keyword(s):  
Laser Ablation ◽  
Antiepileptic Drugs ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Oral Prednisolone ◽  
Hypothalamic Hamartoma ◽  
The Third ◽  
Epileptic Spasms ◽  
Male Patients

Introduction: Hypothalamic hamartoma is rarely associated with epileptic spasms. We describe epileptic spasms in a large cohort of hypothalamic hamartoma patients. Methods: We performed a retrospective chart review between March 2011 and March 2020 to identify patients with hypothalamic hamartoma and epilepsy. Results: We identified 114 patients with hypothalamic hamartoma and epilepsy, only 3 male patients (2.6%) also had epileptic spasms. The epileptic spasms developed between 6 and 18 months of age. Epileptic spasms resolved with oral prednisolone in 1 and with vigabatrin in the second patient. The third patient continued epileptic spasms despite multiple antiepileptic drugs and partial resection of hypothalamic hamartoma. All 3 patients underwent laser-ablation of hypothalamic hamartoma at the age of 14, 29, and 63 months. The seizure burden decreased by 100%, 84%, and 93% at follow-up (3-47 months). Conclusions: Epileptic spasms are rare in hypothalamic hamartoma patients and early laser-ablation could potentially treat epileptic spasms and all other seizure types associated with hypothalamic hamartoma.

Drug-Induced Movement Disorders

2015 ◽  
Vol 25 (2) ◽  
pp. 70-77
Author(s):  
Amy Lustig ◽  
Cesar Ruiz
Keyword(s):  
Movement Disorders ◽  
Medical Management ◽  
Disease Process ◽  
Underlying Disease ◽  
Extrapyramidal Symptoms ◽  
Drug Induced ◽  
General Overview ◽  
Management Approaches ◽  
Broad Understanding ◽  
Underlying Disease Process

The purpose of this article is to present a general overview of the features of drug-induced movement disorders (DIMDs) comprised by Parkinsonism and extrapyramidal symptoms. Speech-language pathologists (SLPs) who work with patients presenting with these issues must have a broad understanding of the underlying disease process. This article will provide a brief introduction to the neuropathophysiology of DIMDs, a discussion of the associated symptomatology, the pharmacology implicated in causing DIMDs, and the medical management approaches currently in use.

1438: Benign Prostatic Hyperplasia Outcomes 12 Months after Initiating Medical Management: An Analysis of Managed Care Data

2006 ◽  
Vol 175 (4S) ◽  
pp. 464-465
Author(s):  
Michael J. Naslund ◽  
Muta M. Issa ◽  
Libby Black ◽  
Michael Eaddy ◽  
Manan Shah
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Managed Care ◽  
Medical Management ◽  
Prostatic Hyperplasia

7: Differences in Medical Management of LUTS/BPH between PCPS and Urologists

2006 ◽  
Vol 175 (4S) ◽  
pp. 3-3 ◽  
Author(s):  
John T. Wei ◽  
James Nuckolls ◽  
Martin Miner ◽  
Raymond C. Rosen ◽  
Claus G. Roehrborn
Keyword(s):  
Medical Management
Sign in / Sign up

Export Citation Format

Share Document